Statistics from Altmetric.com
The homothety factor, as defined by Bokov and Delclaux,1 describes a structural aspect of the airway tree not directly addressed in our study, which we agree is important and likely also influences airflow in asthma and COPD. However, we believe the suggestion that the two factors, tracheal area and homothety factor, alone characterise the whole bronchial tree omits important structural characteristics, such as airway lengths and branch angles, which also influence airflow.3 ,4 We have been quite interested in the role played by airway geometry in assessing disease-specific airflow patterns and distribution patterns of inhaled particles.5
Bokov and Delclaux hypothesise that narrowing and removal of the smallest airways in COPD leave larger airways to be detected by CT.1 We agree that this is a logical conclusion of our results; however, it does not bias our results as stated, because we compared airways at matched hierarchical locations.2 Indeed, our findings support the recommendation that comparative studies of airway morphology by disease state using CT or any other technique, should ensure similar hierarchical locations of sampled airways between groups to avoid bias introduced from the hierarchical gradient of airway properties in the tracheobronchial tree.6
We agree that airway dimensions are important in diseases other than COPD and, similar to the writers, have found markedly smaller airway lumen diameters in patients with asthma—including adults with a history of remitted childhood asthma.7
Most certainly, as Bokov and Delclaux emphasise, airway structure, both inherent and acquired, plays a critical role in regard to regional lung function and environmental impact on the lung. With the detailed anatomy available from advances in imaging technologies, a wealth of new data is available for exploration.
Contributors BMS contributed to the discussion, formulation, drafting and revising of this correspondence, and is responsible for the overall content as guarantor. EAH contributed to the discussion, formulation and revising of this letter. RGB contributed to the discussion, formulation and revising of this letter.
Funding Funding Institutions: U.S. Department of Health and Human Services-National Institutes of Health. Grant Number: HHSN2682009000019C and HHSN268200900020C; HHSN268200900013C, HHSN268200900014C; HHSN268200900015C, HSN268200900016C; HHSN268200900017C, HHSN268200900018C; N01-HC95159-HC95169; R01-HL093081, R01-HL077612, R01-HL075476. Fonds de Recherche du Québec—Santé.
Competing nterests: EAH is a founder and shareholder of VIDA Diagnostics, a company that is commercialising pulmonary image analysis software developed, in part, at the University of Iowa.
Provenance and peer review Not commissioned; internally peer reviewed.